


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
“ANLOTINIB HYDROCHLORIDE CAPSULES”
OBTAINED APPROVAL FOR THE FIFTH INDICATION

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Anlotinib Hydrochloride Capsules” (“**Anlotinib**”) (brand name: “**FOCUS V**”), an anti-tumor drug self-developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the PRC, for the indication of locally advanced or metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) which is inoperable. It is the fifth indication that Anlotinib has obtained approval, following the approval obtained for the treatment of advanced non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, and medullary thyroid cancer.

With the approval for the indication of RAIR-DTC, Anlotinib has become the first domestic brand name innovative targeted drug that has obtained approval for such indication, which has not only revolutionized the treatment landscape of relapsed/metastatic RAIR-DTC, but also provided a new and powerful medication option for patients in China.

The Group is creating wide-scope deployment for combination therapies of Anlotinib with chemotherapy, PD-1, and PD-L1. Currently, more than 20 clinical trials for Anlotinib have entered Phase II or Phase III. At the 2021 Meeting of American Society of Clinical Oncology (ASCO), the Group released data from 40 studies on the application of Anlotinib to 13 major types of cancers, fully demonstrating the potential for future development of Anlotinib.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 19 April 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.